The strong correlation between ADAM33 expression and airway inflammation in chronic obstructive pulmonary disease and candidate for biomarker and treatment of COPD.
ADAM Proteins
/ biosynthesis
Aged
Aged, 80 and over
Biomarkers
/ metabolism
Case-Control Studies
Female
Gene Expression Regulation
Humans
Inflammation
Linear Models
Lung
/ metabolism
Male
Middle Aged
Polymorphism, Single Nucleotide
Pulmonary Disease, Chronic Obstructive
/ metabolism
RNA, Messenger
/ metabolism
Respiratory System
Smoke
/ adverse effects
Solubility
Translational Research, Biomedical
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
21
07
2021
accepted:
19
11
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Airway inflammation in patients with chronic obstructive pulmonary disease (COPD) is an amplified response of the normal immune system that occurs as a result of chronic irritation by toxic substances, such as cigarette smoke. This leads to the characteristic pathological changes in the inflammatory cells of COPD patients. ADAM33 has been reported to be involved in the pathogenesis of COPD in East Asia by affecting airway inflammation and other immune responses. The aim of this study was to determine the potential role of ADAM33 (mRNA and soluble levels) as a biomarker of inflammation in COPD patients. This is a case control study using consecutive sampling. The COPD case and control (non-COPD) groups comprised 37 and 29 patients, respectively. We used univariate analysis to assess differences in the parameters between the groups and bivariate analysis to non-parametrically compare these parameters between the two groups. We observed significantly higher mRNA levels of ADAM33 in the COPD patients (10.39 ± 1.76) as compared to that in the non-COPD individuals (6.93 ± 0.39; P < 0.001). The levels of soluble ADAM33 were also significantly higher in the COPD patients (2.188 ± 1.142 ng/ml) compared to the non-COPD individuals (0.487 ± 0.105 ng/ml; P < 0.001). The mRNA and soluble ADAM33 levels were significantly higher in COPD patients compared to those in the parameter-matched non-COPD individuals. Thus, ADAM33 is a potential biomarker and treatment for inflammation in COPD patients.
Identifiants
pubmed: 34848800
doi: 10.1038/s41598-021-02615-2
pii: 10.1038/s41598-021-02615-2
pmc: PMC8632976
doi:
Substances chimiques
Biomarkers
0
RNA, Messenger
0
Smoke
0
ADAM Proteins
EC 3.4.24.-
ADAM33 protein, human
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23162Informations de copyright
© 2021. The Author(s).
Références
BMC Res Notes. 2010 Mar 16;3:72
pubmed: 20233391
Ann Med Surg (Lond). 2020 Dec 19;61:44-47
pubmed: 33384873
Respir Res. 2017 Jan 5;18(1):7
pubmed: 28056993
BMC Pulm Med. 2014 Nov 04;14:173
pubmed: 25369941
Int J Chron Obstruct Pulmon Dis. 2014 Jul 29;9:735-43
pubmed: 25114519
Respir Res. 2008 May 29;9:47
pubmed: 18510721
Respir Res. 2014 Aug 26;15:104
pubmed: 25155252
Ann Med Surg (Lond). 2021 Feb 12;63:102174
pubmed: 33664952
Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):47-55
pubmed: 26123447
Mol Biol Rep. 2015 Feb;42(2):409-22
pubmed: 25280544
Postgrad Med J. 2007 Apr;83(978):244-50
pubmed: 17403951
J Oncol. 2017;2017:6209849
pubmed: 29225623
BMC Res Notes. 2017 Jun 12;10(1):202
pubmed: 28606156
Ann Med Surg (Lond). 2021 Apr 01;65:102262
pubmed: 33898034
Evid Based Complement Alternat Med. 2018 May 13;2018:1281420
pubmed: 29861765
Am Rev Respir Dis. 1963 May;87:684-93
pubmed: 14015517
J Allergy Clin Immunol. 2007 Apr;119(4):863-71
pubmed: 17339047
Saudi J Anaesth. 2018 Jul-Sep;12(3):395-398
pubmed: 30100837
BMC Med Genet. 2009 Dec 10;10:132
pubmed: 20003279
J Allergy Clin Immunol. 2007 Jan;119(1):89-97
pubmed: 17208589
Respir Med Case Rep. 2018 Feb 25;23:158-162
pubmed: 29719807
J Allergy Clin Immunol. 2008 Jun;121(6):1400-6, 1406.e1-4
pubmed: 18410963